YUTREPIA now available to be prescribed to patients via specialty pharmaciesFDA approved YUTREPIA on May 23, 2025Court denies United Therapeutics’ request for preliminary injunction and a temporary ...

This decision came after the full FDA approval of YUTREPIA inhalation powder for adults with pulmonary arterial hypertension ...

Liquidia shares climbed 7.5% after disclosing that it is scheduled to make its first commercial shipment of Yutrepia inhalation powder, days after Food and Drug Administration approval. Shares were ...

United Therapeutics Corp. (UTC) and Liquidia Technologies Inc. have been battling for close to a decade over their respective inhaled formulations ...

Dr. Roger Jeffs, CEO, Liquidia said: “We have moved with exceptional speed to provide a new and differentiated therapeutic alternative to the marketplace. In just over one week, our sales ...

MORRISVILLE, N.C., June 02, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary ...

Investing.com -- Shares of Liquidia Technologies Inc (NASDAQ:LQDA) were up 9.6% following the announcement that the company is scheduled to make its first commercial shipment of YUTREPIA ...

(RTTNews) - Liquidia Corporation (LQDA), a biopharmaceutical company, announced Monday that it has made its first commercial shipment of YUTREPIA or treprostinil inhalation powder, following FDA ...

Dr. Roger Jeffs, CEO, Liquidia said: "We have moved with exceptional speed to provide a new and differentiated therapeutic alternative to the marketplace. In just over one week, our sales force hit ...

On Monday, Needham analysts adjusted their outlook on Liquidia Technologies (NASDAQ:LQDA), raising the stock’s price target to $32 from $25 while maintaining a Buy rating. This change follows a ...